Kiarra Durand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kiarra Durand has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Jason P. Acker
Department of Laboratory Medicine and Pathology University of Alberta Edmonton Alberta Canada
2 shared publications - Aducio Thiesen
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB T6G 2R3, Canada
1 shared publication - Andrew Mark James Shapiro
Clinical Islet Transplant Program, University of Alberta, Edmonton, Canada
1 shared publication - Carly Olafson
Innovation and Portfolio Management, Canadian Blood Services, Edmonton, Alberta, Canada; Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
1 shared publication - Carly Olafson
Innovation and Portfolio Management Canadian Blood Services Edmonton Alberta Canada
1 shared publication - Celina Phan
Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
1 shared publication
Latest Publications
- Open Access
- 7 June 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1811-1820
Plasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion
- 7 June 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (11) , 1811-1820
Open AccessPlasma-supplemented red cell concentrates as alternatives to whole blood in porcine ex vivo heart perfusion
- Open Access
- 6 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2496
Model of Acute Liver Failure in an Isolated Perfused Porcine Liver—Challenges and Lessons Learned
Acute liver failure (ALF) is a rare but devastating disease associated with substantial morbidity and a mortality rate of almost 45%. Medical treatments, apart from supportive care, are limited and liver transplantation may be the only rescue option. Large animal models, which most closely represent human disease, can be logistically and technically cumbersome, expensive and pose ethical challenges. The development of isolated organ perfusion technologies, originally intended for preservation before transplantation, offers a new platform for experimental models of liver disease, such as ALF. In this study, female domestic swine underwent hepatectomy, followed by perfusion of the isolated liver on a normothermic machine perfusion device. Five control livers were perfused for 24 h at 37 °C, while receiving supplemental oxygen and nutrition. Six livers received toxic doses of acetaminophen given over 12 h, titrated to methemoglobin levels. Perfusate was sampled every 4 h for measurement of biochemical markers of injury (e.g., aspartate aminotransferase [AST], alanine aminotransferase [ALT]). Liver biopsies were taken at the beginning, middle, and end of perfusion for histological assessment. Acetaminophen-treated livers received a median dose of 8.93 g (8.21–9.75 g) of acetaminophen, achieving a peak acetaminophen level of 3780 µmol/L (3189–3913 µmol/L). Peak values of ALT (76 vs. 105 U/L; p = 0.429) and AST (3576 vs. 4712 U/L; p = 0.429) were not significantly different between groups. However, by the end of perfusion, histology scores were significantly worse in the acetaminophen treated group (p = 0.016). All acetaminophen treated livers developed significant methemoglobinemia, with a peak methemoglobin level of 19.3%, compared to 2.0% for control livers (p = 0.004). The development of a model of ALF in the ex vivo setting was confounded by the development of toxic methemoglobinemia. Further attempts using alternative agents or dosing strategies may be warranted to explore this setting as a model of liver disease.
- 6 October 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (10) , 2496
Open AccessModel of Acute Liver Failure in an Isolated Perfused Porcine Liver—Challenges and Lessons Learned
Acute liver failure (ALF) is a rare but devastating disease associated with substantial morbidity and a mortality rate of almost 45%. Medical treatments, apart from supportive care, are limited and liver transplantation may be the only rescue option. Large animal models, which most closely represent human disease, can be logistically and technically cumbersome, expensive and pose ethical challenges. The development of isolated organ perfusion technologies, originally intended for preservation before transplantation, offers a new platform for experimental models of liver disease, such as ALF. In this study, female domestic swine underwent hepatectomy, followed by perfusion of the isolated liver on a normothermic machine perfusion device. Five control livers were perfused for 24 h at 37 °C, while receiving supplemental oxygen and nutrition. Six livers received toxic doses of acetaminophen given over 12 h, titrated to methemoglobin levels. Perfusate was sampled every 4 h for measurement of biochemical markers of injury (e.g., aspartate aminotransferase [AST], alanine aminotransferase [ALT]). Liver biopsies were taken at the beginning, middle, and end of perfusion for histological assessment. Acetaminophen-treated livers received a median dose of 8.93 g (8.21–9.75 g) of acetaminophen, achieving a peak acetaminophen level of 3780 µmol/L (3189–3913 µmol/L). Peak values of ALT (76 vs. 105 U/L; p = 0.429) and AST (3576 vs. 4712 U/L; p = 0.429) were not significantly different between groups. However, by the end of perfusion, histology scores were significantly worse in the acetaminophen treated group (p = 0.016). All acetaminophen treated livers developed significant methemoglobinemia, with a peak methemoglobin level of 19.3%, compared to 2.0% for control livers (p = 0.004). The development of a model of ALF in the ex vivo setting was confounded by the development of toxic methemoglobinemia. Further attempts using alternative agents or dosing strategies may be warranted to explore this setting as a model of liver disease.